纳米脂质体药物在类风湿性关节炎治疗中的研究进展

Nanoliposomes in treatment of rheumatoid arthritis

类风湿性关节炎(RA)是一种病因未明的自身免疫性疾病,典型病理改变为慢性滑膜炎,严重影响患者生活质量。目前的治疗药物能够缓解症状,延缓病程,但均存在明显的不良反应。以脂质体为代表的纳米药物递送系统在临床上已显现出了明显的优势,其能够通过被动或主动靶向从而提高药物的治疗效应及减少不良反应。在本文中,我们回顾了脂质体药物递送系统在RA治疗中的作用,阐述了其在临床前研究和临床试验的进展,并讨论了可能阻碍其临床转化的因素。

Rheumatoid arthritis is an autoimmune disease of unknown etiology.The typical pathological change is chronic synovitis,which significantly affects the patients'quality of life.Current drugs can relieve symptoms and delay the disease cours,but there are obvious adverse reactions.Nano-drug delivery systems represented by liposomes have shown obvious clinical advantages,and can improve the therapeutic effect of drugs through passive or active targeting.In this study,we review the role of liposomal drug delivery systems in the treatment of rheumatoid arthritis,describe their progress in preclinical studies and clinical trials,and discuss factors which may hinder their clinical translation.